Login

NON-SUBSCRIBER OPTIONS
FREE TRIAL   |   NEWSSTAND

Providing a steady flow of breaking news, analysis, news briefs, document texts and more, all designed to ensure you have the best, most complete information available anywhere about what’s happening in drug pricing.

When Inbrija was close to market, Acorda Therapeutics wanted to sell the Parkinson’s therapy for $350, but consultants and pharmacy benefit managers made the company set the list price at $950, according to Ron Cohen, who founded Acorda and is the president and CEO of the company.


Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on the coming Democrat-controlled House of Representatives, drug pricing reforms, Medicaid policy, FDA news and much more.